Metabolic bone disease. Current status of diagnosis and treatment
Abstract
Metabolic bone disease is a general term, which encompasses a series of disorders that affect osteological health, due to the occurrence of imbalances in the metabolism of bone tissue, which can affect mineral density, structure, bone remodeling and bone strength, with the presence of the disturbance of the normal balance between bone resorption and bone formation. Therefore, it is crucial to recognize that there are several conditions that impact bone metabolism in different ways, resulting in fragility and increased risk of fractures, as well as, the appearance of pathologies such as osteoporosis or osteochondensation. The objective of this research is to describe the current status of diagnosis and treatment of metabolic bone disease. The importance of the use of treatments such as vitamin D supplements, calcium and bisphosphonates was highlighted, as well as hormonal treatments (calcitonin) that regulate the mineral mechanism, and in the worst cases, surgical intervention to correct deformities or stabilize bones.
Keywords: mineral density, metabolic disturbance, bone remodeling, calcitonin
Downloads
References
Ruoyu Z, Qiaoyue G, Ye X, Qi G, Yan H, Changjun L,et.al. Endocrine role of bone in the regulation of energy metabolism. Bone Res.2021 May [citado 04/04/25]20;9:25. Disponible en:
https://pmc.ncbi.nlm.nih.gov/articles/PMC8137703/pdf/41413_2021_Article_142.pdf
Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer A , Siris ES ,et.al. The clinician's guide to prevention and treatment of osteoporosis. Osteoporos Int. 2022 Oct [citado 04/04/25]; 33(10):2049-2102. Disponible en: https://pmc.ncbi.nlm.nih.gov/articles/PMC9546973/pdf/198_2021_Article_5900.pdf
Bolster MB. Osteoporosis. Manual MSD.USA: Merck & Co;2023.Disponible en:
Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, et.al. American association of clinical endocrinologists practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract.2020 May[citado 04/04/25];26(Suppl 1):1-4. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32427503/
Rodríguez Ramos JF, Herrera Miranda GL. Guía de práctica clínica para la atención a niños y adolescentes con enfermedad renal crónica. MEDISAN.2024 Abr [citado 04/04/25]; 28(2):1-8. Disponible en: http://scielo.sld.cu/pdf/san/v28n2/1029-3019-san-28-02-e4568.pdf
Ospina Caicedo AI, Gómez Escobarb VE, Coy Urreac VA, Segura Charryd JS, Izquierdo Loaizae JH. Enfermedad de Paget de hueso esporádica. Serie de casos y revisión de la literature. Rev. Colombiana de Reumatología.2020 [citado 04/04/25];27(2):103-111. Disponible en:
Wenxiang C, Huiying Y, Xuesheng J. Effects of romosozumab on low bone mineral density or osteoporosis in postmenopausal women: a systematic review. Ann Joint 2020 [citado 04/04/25];5:18.Disponible en: https://aoj.amegroups.org/article/view/5634/pdf
Ammarin S, Chotetawan T, Krasean P, Srihatach N, Suchanant C, Aree T, Cummings SR, Melton LJ. Changes of bone turnover markers and bone mineral density among postmenopausal Thai women with osteoporosis receiving generic risedronate. BMC Women's Health.2024. [citado 04/04/25];24(572):2-9. Disponible en:
https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-024-03404-5
Donovan Walker M, Shane Lacey E, Timms E, Tan HL. Postmenopausal Osteoporosis. N Engl J Med. 2023. [citado 04/04/25]; 389:1979-1991. Disponible en:
https://www.nejm.org/doi/full/10.1056/NEJMcp2307353
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Hodsman AB.et.al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 [citado 04/04/25];344(19):1434-41. Disponible en:
Oryan A, Alidadi S, Moshiri A. Bone Regeneration: A Review of Current Treatment Strategies. J. Clin. Med. 2025[citado 04/04/25]; 14(6): 1838. Disponible en:
https://www.mdpi.com/2077-0383/14/6/1838
Tudorancea IM, Solcan C, Alexa-Stratulat T, Cumpăt MC, Cojocaru DC, Bild V. JWH-182: a safe and effective synthetic cannabinoid for chemotherapy-induced neuropathic pain in preclinical models. Scientific Reports.2024 [citado 04/04/25];14: 16242. Disponible en: https://www.nature.com/articles/s41598-024-67154-y
Published
How to Cite
Issue
Section
License
ACCESS AND DISTRIBUTION POLICY
All published articles are open access contributions, which are distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided that the primary source of publication is properly cited.
